Immuno Research Inc.(IRI) was established in 1997 to develop carbohydrate immune modulators for a wide range of potential applications, including pharmaceuticals and food ingredients with immune-support benefits.
The company has amassed world-class expertise in yeast beta 1,3/1,6 glucans, and has created an extraordinary technology platform for engaging and directing innate and adaptive immune responses. IRI’s technology is protected by more than 100 patents and patents pending.
We have successfully commercialized specific aspects of our technology through exclusive licensing agreements for:
- Therapeutics: clinical development of cancer immunotherapies
- Food ingredients/supplements